Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: A 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial

Menopause

Volumn 20, Issue 1, 2013, Pages 28-37

  Pinkerton, Joann V ^a   Constantine, Ginger ^b   Hwang, Eunhee ^c   Cheng, Ru Fong J ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b EndoRheum Consultants LLC   (United States)

^c PFIZER INC   (United States)

Author keywords

Desvenlafaxine; Hot flash; Menopause; Serotonin norepinephrine reuptake inhibitor; Vasomotor symptoms

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MENTAL DISEASE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SLURRED SPEECH; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 84872071132     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31826421a8     Document Type: Article

References (36)

1. Bruck K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. In: Schonbaum E, Lomax P, eds. Thermoregulation: Physiology and Biochemistry. New York, NY: Pergamon Press, Inc. 1990:255-307.
2. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Women Ment Health 2007;10:247-257.
3. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-3283.
4. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166.
5. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274.
6. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:568-575.
7. Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008; 121:159-162.
8. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
9. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
10. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
11. Pristiq [Package Insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc. (a subsidiary of Pfizer Inc.), 2011.
12. Pfizer pipeline as of February 28, 2012. Available at: http://www.pfizer. com/research/product-pipeline/product-pipeline.jsp. Accessed May 2, 2012.
13. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, for the Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009; 200:238.e1-238.e10.
14. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A doubleblind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10.
15. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo-and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20.
16. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87.
17. Archer DF, Pinkerton JV, Guico-Pabia C. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine over 1 year in women with vasomotor symptoms associated with menopause. Presented at the 22nd Annual Meeting of The North American Menopause Society, Washington, DC, September 21-24, 2011.
18. Gatchel RJ, Lurie JD, Mayer TG. Minimal clinically important difference. Spine 2010;35:1739-1743.
19. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:171-184.
20. Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698-705.
21. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis 2007;66(suppl 3):iii40-iii41.
22. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109-114.
23. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29: 25-31.
24. Greene Climacteric Scale. Corporate Translations, Inc. Available at: http://greeneclimactericscale.com/instrument-information. Accessed December 9, 2011.
25. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industryVestrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptomsVrecommendations for clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338. pdf. Accessed October 31, 2011.
26. International Conference on Harmonisation. ICH harmonised tripartite guideline: statistical principles for clinical trials E9. International Conference on Harmonisation 1998. Available at: http://www.ich.org/products/ guidelines/efficacy/efficacy-single/article/statistical-principles-for- clinicaltrials. html. Accessed April 30, 2012.
27. Maughan EF, Lewis JS. Outcome measures in chronic low back pain. Eur Spine J 2010;19:1484-1494.
28. Michener LA, McClure PW, Sennett BJ. American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form, patient self-report section: reliability, validity, and responsiveness. J Shoulder Elbow Surg 2002;11:587-594.
29. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118(suppl 12B):74-78.
30. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2009;16:132-140.
31. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17A-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779.
32. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-195.
33. Shelton RC. Serotonin norepinephrine reuptake inhibitors: similarities and differences. Prim Psychiatry 2009;15:25-35.
34. Gallagher JC, Strzinek RA, Cheng RF, Ausmanas MK, Astl D, Seljan P. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health (Larchmt) 2012;21:188-198.
35. Loprinzi CL, Barton DL. On hot flash mechanism, measurement, and treatment. Menopause 2009;16:621-623.
36. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823-830.